Previously, low FBXO21 expression was reported to be associated with a poor prognosis in patients with GC, and FBXO21 was found to inhibit the progression of GC by suppressing proliferation and epithelial-to-mesenchymal transition [40]. This evidence concerns the gene FBXO21 and gastric cancer.